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ABSTRACT 
 
Platelet binding is a critical step in the development of Infective Endocarditis (IE), an infection 
of the endocardium. However, the mechanisms utilized by IE causing species for binding to 
platelets remain understudied. Subacute IE, is associated with previously damaged heart valves 
and is often caused by the bacterial species Streptococcus oralis. S. oralis binds sialic acid, a 
host carbohydrate found on the surface of platelets. A novel sialic acid binding adhesin, AsaA, 
was identified in S. oralis. We identified orthologs of AsaA in two other bacterial species that 
cause IE, Gemella haemolysans and Granulicatella elegans. Our hypothesis is that AsaA 
mediates adherence of multiple species. G. haemolysans was selected for further study and 
shares 62% predicted amino acid identity with the non-repeat region of AsaA from S. oralis. G. 
haemolysans has rarely been studied, so we began by optimizing growth conditions. Binding of 
the species to platelets was consistently low which prevented the direct assessment of the role of 
G. haemolysans AsaA in adhesion. Given the same sialic acid binding specificities, the 
adherence of S. oralis to platelets can be competitively inhibited by recombinant proteins that 
bind terminal sialic acid. Hence, we recombinantly expressed the binding region of AsaA from 
G. haemolysans (AsaA_NRGh) and observed the impact of the protein on the adherence of S. 
oralis to platelets. AsaA_NRGh competitively inhibited adhesion of S. oralis to platelets in an 
AsaA dependent manner. This finding supports the hypothesis that G. haemolysans AsaA acts as 
an adhesin. If AsaA is a conserved mechanism of adhesion, a single treatment or preventative 
measure may target multiple IE causing species.    
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INTRODUCTION 
 
Infective endocarditis (IE), an infection (usually bacterial) of the heart endocardium, continues to 
be associated with high rates of morbidity and mortality. The disease is associated with a 20 
percent in-hospital mortality rate and 40 percent one year mortality rate post diagnosis (1-4). The 
incident rate of IE has not decreased over the past 20 years and may even indicate an upward 
trend (1-3,5). IE disproportionately impacts the elderly as the elderly populations more often 
have risk factors associated with the disease such as calcific valvular lesions and prosthetic 
valves (6). IE often requires hospital treatment, including intravenous antibiotics and surgery. An 
estimated 40 to 50 percent of patients infected with IE have to undergo surgery (3). Since there 
have been no significant improvements in the recent survival rate of patients diagnosed with IE, 
it is important we continue to study the mechanisms by which the disease develops. 
Understanding these mechanisms may point to a new preventative measure or treatment option.  
There are two subsets of IE: acute and subacute. Acute IE is typically associated with previously 
normal heart valves and is rapid in presentation. Symptoms such as high fevers and sepsis are 
often associated with the rapid onset of the disease (7). Acute IE is commonly caused by 
staphylococcal species such as Staphylococcus aureus. (8). Alternatively, subacute IE is typically 
associated with previously damaged valves and is often caused by streptococcal species. 
Symptoms of subacute IE vary and include congestive heart failure and valvular incompetence. 
In comparison to acute IE, subacute IE is more gradual in presentation (3). In subacute IE, the 
damaged endocardial surface promotes binding of platelets and fibrin. Platelets and fibrin 
complex to form a nidus, a focus of infection, which then becomes infected with bacteria 
circulating in the blood. Bacteria may bind directly to this nidus or bind to circulating platelets 
which then adhere to the damaged endothelial surface. (9-11). Although it is unclear which path 
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bacteria follow, it is well accepted these bacteria bind to platelets. Electron microscopy 
confirmed bacterial adherence to platelets in a rabbit model for IE. (12). Once bacterial 
colonization has occurred growth of the bacteria in conjunction with host processes including 
activation of the coagulation system and deposition of fibronectin lead to vegetative growths. 
These vegetative growths result in the clinical effects of IE such as congestive heart failure 
(10,11,13).  Previous studies have identified viridans group streptococci, which can enter the 
bloodstream from the oral cavity (3, 14-17), as common causes of subacute IE. It is widely 
appreciated that two viridans group streptococcal species Streptococcus gordonii and 
Streptococcus sanguinis bind to platelets. Adherence of these bacterial species to host 
carbohydrates on platelets is an important step in the development of IE. Specifically, these 
species bind to sialic acid, a host carbohydrate present on the surface of platelets (18-20). The 
binding of these species to sialic acid on platelets is mediated by serine-rich repeat proteins 
(SRRPs) (13, 18, 20-22). Mutagenesis of SRRPs found in streptococci have resulted in reduced 
pathogenesis of IE in a rat model (23-25). SRRPs are a family of bacterial adhesins that mediate 
adherence to host and bacterial surfaces (26-31).  SRRPs contain two glycosylated serine-rich 
repeat (SRRs) regions that flank a non-repeat region (NRR) which is responsible for binding to 
host and/or bacterial surfaces. (27). Different SRRPs can bind to different receptors dependent 
on the domains within the NRR. SRRPs have been identified in both S. gordonii and S. sanguinis 
that contain a sialic acid-binding immunoglobin-type lectin (Siglec)-like domain within the NRR 
of the protein. In addition to sialic acid, SRRPs can bind to receptors including fibrinogen, DNA, 
and keratins. (27,28). Identifying the mechanisms by which bacteria bind to host carbohydrates 
on platelets may provide insight into future preventative measures or therapeutics.  
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The King Lab studies the mechanisms by which the viridans group streptococcal species 
Streptococcus oralis, causes subacute IE. S. oralis is a Gram-positive bacterium that is present in 
normal human oral microbiota. However, as a leading cause of subacute IE, it is also an 
important etiological agent of the disease (15,32). Previous studies performed by King lab with 
S. oralis indicate that similar to other virdians group streptococci, the species binds to host 
carbohydrates present on platelets. S. oralis is composed of three subspecies: S. oralis subsp. 
oralis, S. oralis subsp. tigurinis and S. oralis subsp. dentisani (33,34). All three subspecies have 
been associated with cases of IE (35-38). Investigation of the adherence mechanisms utilized by 
these subspecies will result in a better understanding of the disease.  
Multiple isolates of S.  oralis subsp. oralis encode Fap1, a serine-rich repeat protein (SRRP) that 
mediates binding of the bacterium to sialic acid. Similar to the SRRPs found in S. gordonii and S. 
sanguinis, Fap1 contains a Siglec-like domain which mediates binding of S. oralis subsp. oralis 
to platelets (30). Previous studies have demonstrated sialic acid as a conserved receptor across 
multiple isolates of S. oralis. However, some of these isolates capable of binding to sialic acid 
lack Fap1. This finding demonstrates that Fap1 is not essential for S. oralis binding to terminal 
sialic acid present on platelets. Isolates that lack Fap1 must bind via a distinct SRRP or in an 
SRRP-independent manner. To identify the adhesin responsible for binding to sialic acid, isolate 
IE12, one of the isolates that lacks Fap1, was genome sequenced. Genomic sequencing revealed 
that IE12 did not contain a SRRP. Comparative genomics and structural predictions were utilized 
to identify a cell wall anchored protein named AsaA (associated with sialic acid adhesion A) 
which contains two Siglec-like domains. To directly assess the role of AsaA in binding, an 
asaA mutant was created. There was a significant reduction in the adhesion of the mutant which 
demonstrates AsaA is required for binding of IE12 to platelets. There is no further reduction in 
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adherence of the asaA mutant with the enzymatic removal of sialic acid. This finding 
demonstrates AsaA is specifically required for binding to sialic acid on platelets. To further 
investigate the role of AsaA in adhesion, the NRR region of AsaA from isolate IE12 was 
recombinantly expressed (AsaA_NRSo). The ability of AsaA_NRSo to reduce IE12 adherence 
indicates AsaA is an adhesin. This claim is supported by the dose-dependent reduction in 
adherence of IE12 in the presence of increasing concentrations of AsaA_NRSo. These data 
demonstrate IE12 binds to sialic acid via novel adhesin, AsaA.  
The identification of AsaA prompted the search for other IE causing bacterial species that encode 
for AsaA orthologs in order to determine if AsaA is a conserved mechanism of adhesion across 
different species. Orthologs of AsaA were identified in two other bacterial species that cause IE, 
Gemella haemolysans M341 and Granulicatella elegans ATCC 700633 (39,40).  
G. elegans is a fastidious Gram-positive species and is a component of normal human oral 
microbiota. Prior to reclassification, the species was described as a nutritionally variant 
Streptococcus (41,42). Similar to G. elegans, G. haemolysans is a Gram-positive species and was 
also misidentified as a member of the streptococcal genus (43). This species is normally present 
in the upper respiratory, gastrointestinal, and genitourinary tract (39). Case reports have 
described G. haemolysans as a cause of subacute IE likely entering the bloodstream from the oral 
cavity (44-47). 
The focus of this study was to examine the role of AsaA in binding to platelets across multiple 
bacterial species. We hypothesized that AsaA is a novel family of adhesins that mediates 
adherence of multiple species to sialic acid. Studies were focused on examining the role of AsaA 
in adhesion in G. haemolysans. If AsaA is a conserved mechanism of adhesion, a single 
treatment or preventative measure may target multiple IE causing species.  
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METHODS 
 
Bacterial strains, culture, and media 
Strains used in this study are listed in Table 1. S. oralis subsp. oralis and G. haemolysans were 
grown overnight at 37C and 5% CO2 on tryptic soy agar plates supplemented with 5% sheep’s 
blood (Becton, Dickinson and Co., Sparks, MD). Broth cultures of S. oralis subsp. oralis were 
grown in Todd-Hewitt broth (Becton, Dickinson and Co.) supplemented with 0.2% wt/vol yeast 
extract (Becton, Dickinson and Co.) (THY).  Broth cultures of G. haemolysans were grown in 
Brain Heart Infusion (BHI) supplemented with 5% fetal bovine serum (FBS) (Dworkin). 
Escherichia coli strains were grown at 37C in Luria-Bertani (LB) broth or LB agar plates. E. 
coli grown in broth was shaken at 200 rpm. As appropriate, the medium was supplemented with 
ampicillin (100 g/ml) or kanamycin (500 g/ml) (Thermo Fischer Scientific).   
Unless otherwise specified, all chemicals, substrates, and enzymes were purchased from Sigma-
Aldrich (St. Louis, MO).  
Mutant Generation  
Attempts were made to generate an insertion-deletion mutant of G. haemolysans via allelic 
exchange. First, a 1.5 kb fragment from the NRR of asaA from G. haemolysans M341 was 
amplified with primers A1 and A2. A Janus cassette was also amplified using primers B1 and 
B2. The asaA fragment was blunt-end ligated into pJet1.2/Blunt PCR cloning vector (Thermo 
Fisher Scientific) and the resulting plasmid was linearized with HincII. The Janus cassette was 
then blunt-end ligated with the linearized plasmid to generate plasmid pJET∆asaA. E. coli Stellar 
competent cells (Clontech) were transformed with the ligation product and transformants were 
then selected for on LB agar plates supplemented with kanamycin. The construct was confirmed 
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via PCR. Attempts were made to transform G. haemolysans by growing bacteria in C+Y media 
to an OD600 (optical density measured at a wavelength of 600 nm) of 0.12 +/- 0.02. 50 L of 
culture was added to 950 L C+Y, 10 L CaCl2 (100 mM), and 100 ng of purified plasmid. The 
mix was incubated for 2 hours in a 37C water bath and plated on TS agar plates with 
kanamycin. No transformants were observed.  
Adherence Assays and Platelet Prep 
Assays to determine bacterial binding to human platelets were adapted from Sullam et al (48). 
Blood was collected from healthy donors and no identifying information was collected. The 
blood was collected in 1:5 (vol/vol) acid citrate dextrose solution (56 mM trisodium citrate 
dehydrate, 65 mM citric acid, 100 mM dextrose). Platelet-rich plasma (PRP) was collected by 
centrifugation for 10 mins at 200 x g. PRP was removed with a serological pipette and diluted 
1:4 (vol/vol) in platelet wash buffer (9.3 mM trisodium citrate dehydrate, 5.3 mM citric acid, 
17.3 mM dextrose, 145.5 mM NaCl, pH 6.5). Platelets were collected by centrifugation for 10 
mins at 700 x g and washed twice with platelet wash buffer. Platelets were resuspended in 
platelet wash buffer and fixed with 1% paraformaldehyde for 10 mins at room temperature. 
Platelets were then washed with PBS two times before being resuspended at 1x107/ml. For 
adherence assays, each well of a 96 well microtiter plate was coated with 100 l of platelets and 
incubated at 37C for 1 hour. Following incubation, unbound platelets were removed by three 
washes with PBS. The control wells were coated with 1% bovine serum albumin (BSA) in PBS. 
All wells were blocked with 3% BSA in PBS and incubated for 1 hour at 37C prior to 
adherence assays. 
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Wells were washed two times with PBS prior to the addition of bacteria. Where stated, 
AsaA_NRSo, AsaA_NRGh, or Fap1_NR was mixed with bacterial cells at the specified 
concentration. AsaA_NRGh was recombinantly expressed and purified as described below. 
AsaA_NRSo and Fap1_NR were recombinantly expressed and purified by a postdoctoral 
scientist in the King Lab, Meztlli Gaytan (30). 
Bacteria were grown to an OD600 of 0.5 +/- 0.05 and approximately 1-2 x 105 bacteria in PBS 
were allowed to adhere at 37C for 60 mins. Nonadherent bacteria were removed by three 
washes with PBS and adherent bacteria were lifted with 0.25% trypsin-1mM EDTA. Lifted 
bacteria were enumerated by serial dilution.  
Adherence assays were performed in triplicate on at least three independent occasions and 
bacterial adherence was calculated as a percentage of the inoculum. The data are presented +/- 
the standard deviation (SD) and statistical significance was determined using a two tailed 
Student’s t-test. Data points with P values <0.05 were considered significant.  
Expression and Purification of AsaA_NRGh 
Prior to this study, the NRR of asaA encoding amino acids 50-739 from G. haemolysans was 
amplified using primers A3 and A4. The fragment was cloned into pGex-5X-3 via In-Fusion and 
the product transformed into E. coli stellar. The transformants were selected for on LB plates 
supplemented with ampicillin. PCR and sequencing were utilized to confirm the expression 
construct.  
BL21 competent E. coli (New England Biolabs, Ipswich, MA) were transformed with the above 
construct. Transformants were selected for on LB agar plates supplemented with ampicillin. 
Cultures were inoculated in 5 mL of LB broth supplemented with ampicillin overnight at 37C. 
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The overnight culture was added to 100 mL of LB and grown at 37C under constant shaking. 
Once the culture reached an OD600 of 0.6-0.8, 1mM Isopropyl -D-1-thiogalactopyranoside 
(IPTG) was added to induce expression. The induced culture was incubated at 30C for 4 hours. 
Cells were harvested by centrifugation at 5000 rpm for 10 mins and resuspended in 1/10 the 
original volume of PBS. Cells were lysed using a French press at 20 kPa. Cell debris was 
collected by centrifugation for 30 mins at 14000 rpm. The supernatant was separated from the 
cellular debris. The soluble protein in the supernatant was purified via affinity chromatography 
using Glutathione Sepharose 4B GST-tagged protein purification resin (GE Healthcare Life 
Sciences, Marlborough, MA), followed by elution with 50 mM tris-HCl, 10 mM glutathione and 
dialysis against PBS, yielding concentrated protein. The purified protein was run on an SDS-
page gel to confirm its size (101.6 kDa) and purity. To quantify the protein its absorbance was 
measured at 280 nm.   
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Table 1: Strains used in this study  
 
Strain or plasmid Characteristic(s)/genotypea Source or reference 
Strain 
S. oralis subsp. oralis 
    
SN51445 (IE12) Endocarditis isolate from an 81 year old 
female  
GNRCSa  
IE12asaA asaA::kan/rpsL+rpsL (K56T), Kanr This study 
G. haemolysans  
M341 
  
Isolated from expectorated sputum for 19-
year-old male patient with cystic fibrosis  
  
BEI resourcesb 
Escherichia coli 
Stellar 
  
Cloning Host 
  
Takara 
BL21 (DE3) Expression Host NEB 
Plasmids      
pJet1.2/blunt Cloning vector, Ampr Thermo Fisher Scientific 
pJetasaA pJetasaA::kan; Ampr Kanr This study 
pGex-5x-3 
 
Expression vector; Ampr GE Biosciences 
 
pGex-5x-3 AsaA NRR pGex-5x-3 containing amino acids 50-739 
from the NRR of AsaA from G. 
haemolysans 
This study 
 
a German National Reference Center for Streptococci 
b Strain M341, HM-239 was obtained through BEI resources, NIAID, NIH as part of the Human 
Microbiome Project  
c Ampr, ampicillin resistant; Kanr, kanamycin resistant  
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Table 2: Primers used in this study 
 
Target 
or 
Group 
Name Sequence 5' to 3' Location  
(accession no.) 
asaA A1  AGGTTATGCGCTTTTCAATTCG 48689-48710 
(GL883584.1) 
 
A2  GAAACAGAGCCTTCTCCACTCG 50653-50674 
(GL883584.1) 
 A3  GAAGGTCGTGGGATCAGTGAAGAAGTTTCAAAAAAC 
 
49801-49821 
(GL883584.1) 
 A4  GATGCGGCCGCTCGATCATAAACTTACATATTCTGATA 
 
51851-51888 
(GL883584.1) 
Janus B1  GGGCCCCTTTCCTTATGCTT 
 
2105–2086 
(AF411920.1) 
 B1  CCGTTTGATTTTTAATGGATAATG 773–796 
(AF411920.1) 
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RESULTS 
 
AsaA orthologs were identified in both Gemella haemolysans and Granulicatella elegans 
 
S. oralis IE isolate IE12 can bind to sialic acid, but lacks SRRP Fap1. Sequencing of IE12 
revealed it encodes for sialic acid adhesin, AsaA. Four of the seventeen sequenced strains 
identified as S. oralis subsp. oralis on the NCBI encode for AsaA. In IE12, directly upstream of 
asaA is iga_1 which encodes for a peptidase and directly downstream is pabB which encodes for 
an amino transferase. The discovery of this adhesin prompted the search for AsaA orthologs in 
other IE causing bacterial species to examine if AsaA is a conserved mechanism of adhesion. An 
NCBI BLASTp (protein-protein Basic Local Alignment Search Tool) with AsaA from S. oralis 
revealed AsaA orthologs in two IE causing species, Gemella haemolysans and Granulicatella 
elegans (49).  IE12 AsaA as well as both AsaA orthologs contain a secretion signal (SS), FIVAR 
(found in various architectures) domain, two Siglec and unique domains, an LPxTG cell wall 
anchoring motif, and a series of DUF1542 (domain of unknown function) repeats (Fig. 1). The 
exact number of DUF1542 repeats in both G. haemolysans and G. elegans AsaA is unknown due 
to incomplete genomic sequences available on the NCBI. The NRR of AsaA begins after the SS 
and extends until the second unique domain ends, thus including the FIVAR domain and both 
Siglec and unique domains. Since the NRR of AsaA from IE12 acts as a sialic acid binding 
adhesin, the NRR from G. haemolysans and G. elegans AsaA may also act as an adhesin. 
Similarities in the amino acid content between the NRR from IE12 AsaA and the NRR of G. 
haemolysans and G. elegans AsaA also suggests similarities in the function of the protein. The 
percent amino acid identity between the NRR of IE12 AsaA and the NRR of AsaA in G. 
haemolysans M341 and G. elegans ATCC 700633 is 62% and 64%, respectfully. In addition, the 
NRR of G. haemolysans AsaA and the NRR of G. elegans AsaA share 77% amino acid identity.  
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One strain of G. elegans and five strains of G. haemolysans are available on the NCBI. Of the 
five strains of G. haemolysans, only strain NCTC10459 is a complete genome. Only strain M341 
encodes for AsaA however, due to the incomplete genomic sequences available, the presence of 
asaA within these genomes cannot be ruled out. Other strains of G. haemolysans may contain 
AsaA or an adhesin that promotes the development of IE if the conditions are correct. G. 
haemolysans AsaA was selected for further study. Directly upstream of asaA in G. haemolysans 
M341 is a gene predicted to encode for a nucleotidyl transferase and directly downstream is a 
gene with an unknown function. The genomic location of AsaA in G. haemolysans appears to be 
SS FIVAR
S1 S2
LPxTGDUF1542 X 31
U1 U2
SS
FIVAR
S1 S2U1 U2
LPxTG
DUF1542 x ?
SS
FIVAR
S1 S2U1 U2
DUF1542 x ?
Gemella haemolysans
Granulicatella elegans
Streptococcus oralis
(IE isolate, IE12)
NRR
1 kb
A
Predicted aa identity of AsaA orthologs
B
Fig 1. AsaA orthologs exist in other IE causing species (A) Visual depicting the protein 
domains of AsaA: SS, secretion signal; FIVAR, found in various architectures; S, Siglec (sialic 
acid-binding immunoglobulin-type lectin); U, unique domain; LPxTG, cell wall anchoring motif; 
NRR, non-repeat region (B) Predicted amino acid identity for the NRR of AsaA across various IE 
causing species. 
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different than AsaA in IE12 based on the identification of the genes flanking AsaA in both 
species. In both IE12 and G. haemolysans, the Siglec-like domains of AsaA are postulated to 
mediate binding to sialic acid. The Siglec-like and unique domains of IE12 AsaA shares a 72% 
amino acid identity with the Siglec-like and unique domains of G. haemolysans M341 AsaA 
(Fig. 2). This similarity suggests that like IE12 AsaA, G. haemolysans AsaA mediates adherence 
to sialic acid on platelets. If AsaA is a conserved mechanism of adhesion, a single treatment or 
preventative measure may target multiple IE causing species.  
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AsaA_Ghpred
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AsaA_Sopred
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360
420
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Fig 2. The Siglec-like and unique domains of IE12 AsaA share a high level of sequence
conservation with the Siglec-like and unique domains of G. haemolysans AsaA. Amino
acid alignment between the predicted Siglec-like and unique domains of AsaA in G.
haemolysans and S. oralis IE12. The predicted amino acid location is given at the end of each
line. A. indicates a conserved amino acid residue and a - indicates a gap in the sequence.
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The addition of Fetal Bovine Serum (FBS) enhances the growth of G. haemolysans in vitro  
 
Growth conditions for G. haemolysans needed to be optimized in order to observe significant 
adherence of the species to platelets, which would allow investigation of the role of sialic acid 
and AsaA in the adhesion of G. haemolysans. In order to maximize the adherence of the species 
to platelets, G. haemolysans was grown to various optical densities (OD600) in BHI, the growth 
medium recommended by the Biodefense and Emerging Infections (BEI) resource repository. 
The absolute adherence, expressed as a percentage relative to the inoculum, of G. haemolysans 
to platelets was calculated at an OD600 of 0.4, 0.5, and 0.6. The inoculums were in the range of 
2.33 x 105 to 3.33 x 105 bacteria. The absolute adherence of G. haemolysans to platelets at an 
OD600 of 0.4, 0.5, and 0.6 was 2.3%, 4.5%, and 1.9% respectfully.  An OD600 of 0.5 resulted in 
the maximum observable adherence of G. haemolysans to platelets. However, in order for the 
species to reach this OD600 it had to be left to grow overnight, which prompted attempts to 
enhance the growth in vitro. A prior study had revealed that fetal bovine serum (FBS) increased 
the growth rate of G. haemolysans. (50). The growth of G. haemolysans was measured both with 
and without FBS. The addition of 5% FBS to growth media greatly enhanced growth (Fig. 3) and 
as a result was used for all future experiments. 
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Attempts to construct an asaA mutant in G. haemolysans using natural transformation 
were unsuccessful   
In comparison to other IE causing bacterial species, G. haemolysans has rarely been studied.  
Previous literature on G. haemolysans is mainly limited to case reports and cases of IE caused by 
G. haemolysans are rare (39, 51, 52). Furthermore, there are no genetic tools available for G. 
haemolysans. Our attempts to naturally transform the species were unsuccessful which prevented 
the construction of an asaA mutant. If significant binding of G. haemolysans to platelets was 
observed, an asaA mutant would have permitted the direct assessment of the role of AsaA in 
adhesion of this species. 
Low binding of G. haemolysans to platelets  
To investigate the role of G. haemolysans AsaA in binding, the NRR of AsaA was 
recombinantly expressed (AsaA_NRGh). The initial strategy was to compete binding of G. 
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Fig 3. The addition of FBS enhances the growth of G. haemolysans in vitro. Growth curve 
for G. haemolysans with and without 5% FBS. Optical density was measured at a wavelength of 
600 nm. 
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haemolysans to platelets with AsaA_NRGh. The ability of this protein to competitively inhibit 
the binding of G. haemolysans to platelets would support the hypothesis that G. haemolysans 
AsaA acts as an adhesin. However, low binding of G. haemolysans to platelets prevented testing 
the adherence of this species in the presence of AsaA_NRGh. The absolute adherence of G. 
haemolysans to platelets was on average 3.5%, whereas the absolute adherence for IE12 to 
platelets was around 11% (Fig. 4). The low binding of G. haemolysans to platelets and the 
variability in binding in the presence of neuraminidase (enzyme that cleaves sialic acid) 
prevented the assessment of the role of sialic acid in adhesion of G. haemolysans. The reason for 
low binding of G. haemolysans is unclear and one possible reason is that proteins such as AsaA 
are not being expressed under our in vitro conditions.  
 
 
Recombinantly expressed AsaA_NRGh competitively inhibits binding of S. oralis  
 
Prior experimentation demonstrated AsaA_NRSo competitively inhibited binding of IE12 to 
platelets. These experiments were adapted in order to determine if AsaA_NRGh could also block 
0
2
4
6
8
10
12
14
16
IE12
A
b
s
o
lu
te
 a
d
h
e
re
n
c
e
 (
%
 o
f 
in
o
c
u
lu
m
)
0
2
4
6
8
10
12
14
16
Gh
A
b
s
o
lu
te
 a
d
h
e
re
n
c
e
  
(%
 o
f 
in
o
c
u
lu
m
)
Fig 4. Absolute adherence of S. oralis IE12 and G. haemolysans M341. Absolute adherence,
expressed as a percentage of the inoculum, of bacterial species to platelets. Values are the
means of at least three independent experiments performed in triplicate +/- SD.
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adhesion of IE12, which would support the hypothesis that G. haemolysans AsaA acts as an 
adhesin. Relative adherence, expressed as a percentage, of the IE12 parental strain was 
calculated for each condition. As expected, the positive control, 5 M AsaA_NRSo, 
competitively inhibited adherence of IE12 to platelets (Fig. 5). AsaA_NRGh (5 M) also 
significantly reduced adhesion of IE12 to platelets (Fig 5). AsaA_NRSo and AsaA_NRGh 
reduced the adherence of IE12 to a similar extent which supports the hypothesis that these two 
species share a conserved mechanism of adhesion.  
 
 
To examine if Fap1 and AsaA share a conserved mechanism of adhesion, adherence of IE12 was 
tested in the presence of the recombinantly expressed NRR from Fap1 (Fap1_NR). Fap1 is an 
SRRP that mediates adherence to sialic acid through its single Sigec-like domain. Fap1_NR 
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Fig 5. Recombinantly expressed AsaA_NRGh significantly reduces binding of IE12 to
platelets. Relative adherence, expressed as a percentage of IE12 binding in the presence and
absence of recombinant protein. Values are the means of at least three independent
experiments performed in triplicate +/- SD. *p<0.05, calculated using a two tailed t-test. NS, not
significant
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competitively inhibits adhesion of Fap1 encoding strains (30). However, there was no significant 
reduction in adhesion of IE12 in the presence of Fap1_NR which could be due to the low level of 
sequence identity between Fap1 and AsaA in both S. oralis and G. haemolysans (Fig. 6).  
 
 
The Siglec-like and unique domain of Fap1 shares higher levels of sequence similarity with the 
first Siglec-like and unique domains than the second Siglec-like and unique domains from S. 
oralis and G. haemolysans AsaA. The Siglec-like and unique domain of Fap1 and the first 
Siglec-like and unique domain of AsaA in G. haemolysans and S. oralis IE12 only share 16% 
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Fig 6. Low level of sequence identity between the first Siglec-like and unique domain of
IE12 and G. haemolysans AsaA and the Siglec-like and unique domain of Fap1. Amino acid
alignment between the first predicted Siglec-like and unique domain for AsaA in G. haemolysans
and S. oralis IE12 and the predicted Siglec-like and unique domain for Fap1. A . indicates a
conserved amino acid residue and a - indicates a gap in the sequence.
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amino acid identity (Fig. 6). The inability of Fap1 to significantly reduce binding of IE12 to 
platelets suggests a difference in sialic acid binding specificities of Fap1 and AsaA.  
The reduction in adhesion of IE12 in the presence of AsaA_NRGh is AsaA dependent  
The ability of AsaA_NRGh to competitively inhibit binding of S. oralis to platelets led to the 
question of whether this reduction was AsaA dependent. Once again, AsaA_NRGh (5 m) 
competitively inhibited binding of IE12 to platelets. The asaA IE12 mutant was utilized as a 
positive control and confirmed AsaA is required for efficient adhesion to platelets (Fig. 7). 
AsaA_NRGh (5 m) did not significantly reduce adhesion of the mutant strain which 
demonstrates AsaA_NRGh competitively inhibits the binding of IE12 to platelets in an AsaA 
dependent manner (Fig 7). 
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Fig 7. Recombinantly expressed AsaA_NRGh significantly reduces binding of IE12 to
platelets in an AsaA dependent manner. Relative adherence, expressed as a percentage of
IE12 binding in the presence and absence of recombinant protein. Relative adherence of an
ΔasaA mutant in the presence and absence of recombinant protein is also shown. Values are
the means of at least three independent experiments performed in triplicate +/- SD. *p<0.05,
calculated using a two tailed t-test. NS, not significant
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DISCUSSION  
 
The pathogenesis of subacute IE is not completely understood. Although understudied, a critical 
step in the development of IE is bacterial adherence to platelets. Multiple IE causing species 
encode for an SRRP and/or AsaA, both of which are sialic acid binding adhesins. These findings 
demonstrate that blocking the binding of IE causing bacterial species to sialic acid may be a 
potential drug target. In this study, we examined if AsaA orthologs exist in other IE causing 
species and mediated adhesion to platelets. AsaA orthologs were identified in IE causing species 
G. haemolysans and G. elegans. The recombinantly expressed NRR of AsaA from G. 
haemolysans competitively inhibits binding of IE12 to platelets in an AsaA dependent manner. 
This finding demonstrates a potential conserved mechanism of adhesion between G. 
haemolysans AsaA and IE12 AsaA.  
Previous studies have demonstrated the importance of SRRPs in adherence of IE causing 
bacterial species to sialic acid. Some strains of viridans group streptococcal species S. gordonii, 
S. sanguinis, and S. oralis bind to sialic acid via SRRPs that contain a Siglec-like domain (13, 
18, 20-22). S. oralis IE isolates IE1, IE12, and IE18 bind to sialic acid, but lack Fap1. Genomic 
sequencing of IE12 and comparative genomics revealed a protein, AsaA, predicted to contain 
Siglec-like domains. Given the importance of these domains in mediating adherence to sialic 
acid in IE causing species, the role of AsaA in adhesion was examined. AsaA in IE12 was 
demonstrated to act as a sialic binding adhesin. An NCBI BLASTp using the amino acid 
sequence for the Siglec-like and unique domains in IE12 AsaA revealed similar sequences in G. 
haemolysans M341 and G.  elegans ATCC 700633 (49). A review of the literature about these 
species revealed both G. haemolysans and G. elegans are causative agents of IE (40, 44-46, 53). 
ATCC 700633 is the only G. elegans strain sequenced on the NCBI, but there are four additional 
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strains other than G. haemolysans M341 sequenced. The sequences of these strains are 
incomplete and hence they may encode for AsaA. Alternatively, they may encode for a different 
adhesin that promotes the development of IE if the conditions are correct or it is possible only 
some strains of this species have the ability to cause IE. IE12 AsaA, G. haemolysans AsaA, and 
G. elegans AsaA all contain Siglec-like and unique domains of similar amino acid lengths and 
sequences which lead to the hypothesis that AsaA is a family of sialic acid binding adhesins 
present in various IE causing species. A previous study demonstrated both the Siglec and unique 
domains of an SRRP were required for sufficient sialoglycan binding in S. gordonii (18). Thus, 
the unique domains in AsaA may play a role in mediating adherence to platelets which prompts 
future attempts to isolate their function. DUF 1542 domains have been found in cell surface 
proteins that play a role in antibiotic resistance or cellular adhesion (54). Specifically, these 
domains have been found in S. aureus EbhA, a protein that binds to human fibronectin (55). In 
addition, a previous study demonstrates DUF1542 repeats have been found in Epf (Extracellular 
protein factor) in Streptococcus pyogenes, another IE causing species. These repeats form a 
fiber-like stalk which projects the adhesin domain towards host receptors. Thus, DUF1542 
repeats found in AsaA may assist in projecting the Siglec-like and unique domain towards host 
surfaces (56). 
G. haemolysans AsaA was selected for further study. Examination of the genes that flank asaA 
in G. haemolysans revealed differences in the genomic location of asaA between this species and 
S. oralis IE12. The gene directly upstream of asaA encodes for a nucleotidyl transferase in G. 
haemolysans and for a peptidase in IE12. The gene directly downstream encodes for an amino 
transferase in IE12, while incomplete genomic sequences available for G. haemolysans M341 
prevent identification of the function of the gene directly downstream. 
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In order to investigate the role of G. haemolysans AsaA in adhesion, growth conditions of the 
species were optimized. Brain Heart Infusion (BHI) Broth was suggested as the growth 
conditions for G. haemolysans M341 by the BEI. BHI alone did not support efficient growth of 
G. haemolysans. Investigation of previous attempts to grow G. haemolysans in vitro revealed 
FBS was used to enhance the growth (50). FBS is widely used as a growth supplement for cell 
culture media and provides many components that satisfy the metabolic requirements for cells 
(Sigma Aldrich) Although FBS is primarily used in eukaryotic cell cultures, it has been used in 
liquid cultures of bacterium such as Helicobacter pylori (57). Thus, the previous use of FBS to 
enhance the growth of G. haemolysans was not unexpected. The addition of 5% FBS greatly 
enhanced both the growth rate and growth yield of G. haemolysans. However, the addition of the 
serum may result in unintended effects. FBS could potentially affect the gene expression of G. 
haemolysans and causes changes in the expression of genes including AsaA. Previous literature 
has demonstrated serum influences exopolysaccharide expression in Staphylococcus aureus, a 
leading cause of acute IE (58). An additional study reveals virulence factors in S. aureus were 
significantly expressed in the presence of serum (59). The effect of FBS on gene expression in G. 
haemolysans remains unknown.  
The observed low binding of G. haemolysans to platelets could be explained by changes in 
expression of genes such as asaA under our in vitro conditions. The gene expression of G. 
haemolysans under our in vitro conditions may not reflect that in vivo. Future experiments 
should be aimed at optimizing the binding of the species to platelets. Inability of the species to 
bind to platelets at a significant level prevents the use of mutants, recombinant proteins and 
enzymatic treatments to investigate the adhesion of WT G. haemolysans. Optimizing the binding 
of G. haemolysans would permit these experiments and the assessment of the role of AsaA in G. 
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haemolysans. We were unable to generate an asaA mutant through natural transformation. 
Although attempts to naturally transform the species were unsuccessful, the species may still be 
capable of transformation despite the lack genetic tools available for G. haemolysans. In future 
experimentation, alternative methods such as electroporation could be explored to generate 
mutants.  
Our studies demonstrate AsaA_NRGh can competitively inhibit binding of IE12 to platelets. 
AsaA_NRGh and AsaA_NRSo reduced the adherence of IE12 to platelets to a similar extent, 
which may be a reflection of the high level of sequence conservation between the two proteins. 
This finding suggests a conserved mechanism of adhesion for AsaA in G. haemolysans and S. 
oralis IE12. However, Fap1_NR did not significantly reduce the adhesion of IE12 to platelets. 
Fap1 only contains one Siglec, while AsaA contains two (30). The amino acid identity between 
the Siglec in Fap1 and the first Siglec in G. haemolysans AsaA and IE12 AsaA reveals low 
levels of sequence conservation (Fig. 6) Thus, Fap1 and AsaA may have different sialic acid 
binding specificities. Sialic acids are a diverse group of sugars. The nine carbon backbone is 
common to all sialic acids, but there are variations that can occur at different carbon positions 
(60). Substitutions occur at the 4, 5, 7, 8, and 9 positions and variations in linkages to the 
underlying sugar chain occur at position 2 (61,62). Thus, Fap1 could bind to a different sialic 
acid or sialic acid linkage than AsaA. If this is true, blocking IE12 binding with Fap1 would be 
ineffective as IE12 AsaA would bind to a different sialic acid or sialic acid linkage than Fap1.  
There was no significant difference in the adhesion of the IE12 asaA mutant with and without 
the presence of AsaA_NRGh. Thus, AsaA_NRGh competitively inhibits adhesion of IE12 to 
platelets in an AsaA dependent manner. This finding demonstrates the importance of AsaA as a 
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mechanism for binding to sialic acid and suggest similarities in the binding specificities of IE12 
AsaA and G. haemolysans AsaA.  
Our data suggests we have identified a novel family of sialic acid binding adhesins present in 
various IE causing species. Future efforts could be focused on optimizing the binding of G. 
haemolysans to platelets in order to test adherence with the enzymatic removal of sialic acid. A 
significant reduction in adherence would demonstrate sialic acid is required for maximum 
binding of G. haemolysans to platelets, supporting the importance of sialic acid binding adhesins 
in the pathogenesis of IE. In addition, the binding region of AsaA from IE12 could be replaced 
with the binding region of AsaA in G. haemolysans to see if this domain also mediates 
adherence. The role of G. elegans AsaA in adhesion could also be examined in order to increase 
our understanding of the role of AsaA in adhesion. Continuation of the work to examine if AsaA 
is a conserved mechanism of adhesion across IE causing species could reveal broader clinical 
significance and improve understanding of the pathogenic mechanisms utilized by IE causing 
species.  
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